• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Revenio Group

14.72 EUR+3.23 %21.8. klo 18.29
14,491 following

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.23 %
+17.20 %
+4.69 %
-20.86 %
-34.29 %
-41.00 %
-34.69 %
-75.61 %
+674.74 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
429.34M EUR
Turnover
567.61K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
29.04.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
I wrote a short analysis on Revenio for Salkunrakentaja. Revenio suffered a complete knockout following the Visionix acquisition
8/14/2026, 6:44 AM
by Tomi Lindell
40
Inderes Revenion iCare DRSplus mukana FDA-hyväksytyssä tekoälyratkaisussa... Revenio Group Oyj | Lehdistötiedote | 17.08.2026 klo 09:00:00 EESTRevenion iCare DRSplus -silmänpohjakamera on mukana Yhdysvalloissa FDA:n hyväksymässä tekoälypohjaisessa ratkaisussa, jossa ...
8/17/2026, 6:07 AM
by Tunturisusi
22
OP has updated its estimates (see Zijoittaja’s tweet) The image shows a target price of €18.0 and a reiterated Buy rating. P/E ratios of 14/10/8 for the years '26/'27/'28. Apparently, the market doesn’t believe in the synergies, and the upcoming share issue is also a poison pill....
8/17/2026, 11:47 AM
by Opa
17
Clearly the forum knows better, and the analyst has been on vacation. I suspect many others have been too. I wonder if some confirmation has come through now that the company is issuing a statement, or if they have also just returned from their vacation?
8/17/2026, 7:12 AM
by Juha Kinnunen
16
Inderes – 17 Aug 26 Revenio: iCaren tekoälykumppani sai vihreää valoa FDA:lta - Inderes Ensimmäinen FDA-hyväksyntä iCare-kameran ja tekoälyn yhdistelmälle poistaa epävarmuutta ja tukee laitemyynnin kasvua Yhdysvalloissa. This is likely what caused the positive momentum already on...
8/17/2026, 7:03 AM
by Juha Kinnunen
16
Owners and potential investors are getting a more detailed explanation of what’s going on. With Visionix, there’s a new strategy and integration to handle. There is certainly plenty to explain, as the market hasn’t been convinced at all by what has been shared so far, at least judging...
yesterday
by Opa
15
@Juha_Kinnunen , I mentioned the approval iHealthscreen received for DRS Plus on the forum over a month ago, so it’s not exactly fresh news. Positive, certainly, absolutely.
8/17/2026, 7:07 AM
by Sheikki
12
Read more on our forum
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 29.04.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8.9.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

Press release20.08.2026 klo 15.30

Invitation to Revenio Group’s Capital Markets Day 2026

Revenio Group
Revenio: iCare's AI partner received green light from FDA
Analyst Comment17.08.2026 klo 10.52 by
Juha Kinnunen

Revenio: iCare's AI partner received green light from FDA

The first FDA approval for the combination of the iCare imaging device and AI removes uncertainty and supports growth in device sales in the United States.

Revenio Group
Press release17.08.2026 klo 09.00

Revenio’s iCare DRSplus included in FDA-cleared AI solution for diabetic retinopathy screening

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Revenio, Audiocast, Q2'26
Webcast08.09.2026 klo 15.00

Revenio, Audiocast, Q2'26

Revenio Group
Regulatory press release12.08.2026 klo 13.00

Jukka Kainulainen starts as Revenio CFO on August 24, 2026

Revenio Group
Revenio: iCare strengthens its foothold in the US screening market with EyeCheq partnership
Analyst Comment07.08.2026 klo 08.57 by
Juha Kinnunen

Revenio: iCare strengthens its foothold in the US screening market with EyeCheq partnership

The strategic partnership can expand the availability of iCare devices in the United States.

Revenio Group
Press release06.08.2026 klo 16.00

Revenio Group’s iCare and EyeCheq announce strategic partnership and minority investment

Revenio Group
Regulatory press release05.08.2026 klo 14.00

Revenio’s updated Disclosure Policy is published

Revenio Group
Revenio: Visionix integration progresses as planned
Analyst Comment03.08.2026 klo 09.04 by
Juha Kinnunen

Revenio: Visionix integration progresses as planned

The company aims for an EBITDA improvement of over 20 MEUR through Visionix synergies by the end of 2029.

Revenio Group
Press release31.07.2026 klo 12.50

Revenio provides an update on the Visionix integration progress and announces changes in the U.S. organization

Revenio Group
Regulatory press release30.06.2026 klo 09.00

Revenio Group Corporation’s Board of Directors resolved on the long-term incentive plan’s performance period 2026–2028 and launch of a new restricted share plan

Revenio Group
Regulatory press release12.06.2026 klo 10.00

Revenio Group Corporation: Managers' Transactions – Marc Abitbol Consulting Service Ltd.

Revenio Group
Regulatory press release11.06.2026 klo 12.20

Correction: Changes to the publication dates of Revenio’s financial reports in 2026

Revenio Group
Regulatory press release10.06.2026 klo 19.00

Changes to the publication dates of Revenio’s financial reports in 2026

Revenio Group
Regulatory press release10.06.2026 klo 19.00

Board of Directors of Revenio has established Technology and Integration Committees

Revenio Group
Regulatory press release02.06.2026 klo 10.00

Revenio Group Corporation: Managers' Transactions – Marc Abitbol

Revenio Group
Regulatory press release02.06.2026 klo 10.00

Revenio Group Corporation: Managers' Transactions – Caravelle Capital SAS

Revenio Group
Regulatory press release29.05.2026 klo 16.00

Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act

Revenio Group
Regulatory press release29.05.2026 klo 09.45

New shares issued in Revenio’s directed share issue have been registered with the Finnish Trade Register

Revenio Group
Revenio: Visionix acquisition completed slightly faster than expected
Analyst Comment29.05.2026 klo 09.59 by
Juha Kinnunen

Revenio: Visionix acquisition completed slightly faster than expected

The slightly faster-than-expected closing of the Visionix transaction mechanically raises this year's revenue and earnings estimates.

Revenio Group